Loading clinical trials...
Loading clinical trials...
BK virus infection is one of the causes of renal allograft loss in the current era. Reduction of immunsuppression is the only intervention that prooved to be effective in treating of BK virus in kidney transplant recipient. However, there are evidences from retrospective and prospective studies showed that leflunomide and mTOR inhibitor such as everolimus or sirolimus have positive outcomes in treatment of BK virus in kidney tranplant recipient. The investigators conduct the RCT to compare the efficacy of leflunomide and mTOR inhibitor everolimus, in treatment of BK virus infected patients who do not respond to immunosuppression reduction.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
King Chulalongkorn Memorial Hospital
Bangkok, Bangkok, Thailand
Start Date
February 10, 2021
Primary Completion Date
December 24, 2025
Completion Date
July 1, 2026
Last Updated
December 31, 2025
50
ESTIMATED participants
Everolimus
DRUG
reduced dose tacrolimus and Leflunomide
DRUG
Lead Sponsor
King Chulalongkorn Memorial Hospital
NCT06926894
NCT05224583
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions